Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Copanlisib in Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib and copanlisib in endometrial cancer (EC), ovarian cancer, primary peritoneal cancer (PPC) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 4 weeks and Recommended Phase II Dose up to 4 weeks. Started Apr 2019; status: completed.
02
Drugs
niraparibcopanlisib
03
Conditions
endometrial cancer (EC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03586661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586661.